|
1
|
Hu J, Liu YF, Wu CF, et al: Long-term
efficacy and safety of all-trans retinoic acid/arsenic
trioxide-based therapy in newly diagnosed acute promyelocytic
leukemia. Proc Natl Acad Sci USA. 106:3342–3347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hillestad LK: Acute promyelocytic
leukemia. Acta Med Scand. 159:189–194. 1957. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bernard J, Weil M, Boiron M, Jacquillat C,
Flandrin G and Gemon MF: Acute promyelocytic leukemia: results of
treatment by daunorubicin. Blood. 41:489–496. 1973.PubMed/NCBI
|
|
4
|
Wang ZY and Chen Z: Acute promyelocytic
leukemia: from highly fatal to highly curable. Blood.
111:2505–2515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sanz MA: Arsenic trioxide in the
management of APL: proceed with caution. Oncology (Williston Park).
25:743–746. 2011.PubMed/NCBI
|
|
6
|
Gonzalez-Alegre P, Bode N, Davidson BL and
Paulson HL: Silencing primary dystonia: lentiviral-mediated RNA
interference therapy for DYT1 dystonia. J Neurosci. 25:10502–10509.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ye X, Liu T, Gong Y, Zheng B, Meng W and
Leng Y: Lentivirus-mediated RNA interference reversing the
drug-resistance in MDR1 single-factor resistant cell line
K562/MDR1. Leuk Res. 33:1114–1119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rodriguez M, Aladowicz E, Lanfrancone L
and Goding CR: Tbx3 represses E-cadherin expression and enhances
melanoma invasiveness. Cancer Res. 68:7872–7881. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Artal-Sanz M and Tavernarakis N:
Prohibitin couples diapause signalling to mitochondrial metabolism
during ageing in C. elegans. Nature. 461:793–797. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Merkwirth C and Langer T: Prohibitin
function within mitochondria: essential roles for cell
proliferation and cristae morphogenesis. Biochim Biophys Acta.
1793:27–32. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Týc J, Faktorová D, Kriegová E, Jirků M,
Vávrová Z, Maslov DA and Lukes J: Probing for primary functions of
prohibitin in Trypanosoma brucei. Int J Parasitol. 40:73–83.
2010.PubMed/NCBI
|
|
12
|
Sharma A and Qadri A: Vi polysaccharide of
Salmonella typhi targets the prohibitin family of molecules
in intestinal epithelial cells and suppresses early inflammatory
responses. Proc Natl Acad Sci USA. 101:17492–17497. 2004.
|
|
13
|
Theiss AL, Idell RD, Srinivasan S,
Klapproth JM, Jones DP, Merlin D and Sitaraman SV: Prohibitin
protects against oxidative stress in intestinal epithelial cells.
FASEB J. 21:197–206. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kolonin MG, Saha PK, Chan L, Pasqualini R
and Arap W: Reversal of obesity by targeted ablation of adipose
tissue. Nat Med. 10:625–632. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ferrer I, Perez E, Dalfó E and Barrachina
M: Abnormal levels of prohibitin and ATP synthase in the substantia
nigra and frontal cortex in Parkinson’s disease. Neurosci Lett.
415:205–209. 2007.PubMed/NCBI
|
|
16
|
Mengwasser J, Piau A, Schlag P and Sleeman
JP: Differential immunization identifies PHB1/PHB2 as blood-borne
tumor antigens. Oncogene. 23:7430–7435. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gamble SC, Chotai D, Odontiadis M, Dart
DA, Brooke GN, Powell SM, Reebye V, Varela-Carver A, Kawano Y,
Waxman J and Bevan CL: Prohibitin, a protein downregulated by
androgens, represses androgen receptor activity. Oncogene.
26:1757–1768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peng X, Mehta R, Wang S, Chellappan S and
Mehta RG: Prohibitin is a novel target gene of vitamin D involved
in its antiproliferative action in breast cancer cells. Cancer Res.
66:7361–7369. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gregory-Bass RC, Olatinwo M, Xu W,
Matthews R, Stiles JK, Thomas K, Liu D, Tsang B and Thompson WE:
Prohibitin silencing reverses stabilization of mitochondrial
integrity and chemoresistance in ovarian cancer cells by increasing
their sensitivity to apoptosis. Int J Cancer. 122:1923–1930. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu TF, Wu H, Wang YW, Chang TY, Chan SH,
Lin YP, Liu HS and Chow NH: Prohibitin in the pathogenesis of
transitional cell bladder cancer. Anticancer Res. 27:895–900.
2007.PubMed/NCBI
|
|
21
|
Qi J, He P, Chen W, Wang H, Wang X and
Zhang M: Comparative proteome study of apoptosis induced by As4S4
in retinoid acid resistant human acute promyelocytic leukemia
NB4-R1 cells. Leuk Res. 34:1506–1516. 2010. View Article : Google Scholar
|
|
22
|
McClung JK, Jupe ER, Liu XT and Dell’Orco
RT: Prohibitin: potential role in senescence, development, and
tumor suppression. Exp Gerontol. 30:99–124. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang S, Nath N, Adlam M and Chellappan S:
Prohibitin, a potential tumor suppressor, interacts with RB and
regulates E2F function. Oncogene. 18:3501–3510. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rastogi S, Joshi B, Dasgupta P, Morris M,
Wright K and Chellappan S: Prohibitin facilitates cellular
senescence by recruiting specific corepressors to inhibit E2F
target genes. Mol Cell Biol. 26:4161–4171. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang S and Faller DV: Roles of prohibitin
in growth control and tumor suppression in human cancers. Transl
Oncogenomics. 3:23–37. 2008.PubMed/NCBI
|
|
26
|
Singh S, Johnson J and Chellappan S: Small
molecule regulators of Rb-E2F pathway as modulators of
transcription. Biochim Biophys Acta. 1799:788–794. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ande SR, Xu Z, Gu Y and Mishra S:
Prohibitin has an important role in adipocyte differentiation. Int
J Obes (Lond). 36:1236–1244. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Joshi B, Rastogi S, Morris M, Carastro LM,
DeCook C, Seto E and Chellappan SP: Differential regulation of
human YY1 and caspase 7 promoters by prohibitin through E2F1 and
p53 binding sites. Biochem J. 401:155–166. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fusaro G, Dasgupta P, Rastogi S, Joshi B
and Chellappan S: Prohibitin induces the transcriptional activity
of p53 and is exported from the nucleus upon apoptotic signaling. J
Biol Chem. 278:47853–47861. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He B, Feng Q, Mukherjee A, Lonard DM,
DeMayo FJ, Katzenellenbogen BS, Lydon JP and O’Malley BW: A
repressive role for prohibitin in estrogen signaling. Mol
Endocrinol. 22:344–360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Davis ME, Zuckerman JE, Choi CH, Seligson
D, Tolcher A, Alabi CA, Yen Y, Heidel JD and Ribas A: Evidence of
RNAi in humans from systemically administered siRNA via targeted
nanoparticles. Nature. 464:1067–1070. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Moffat J, Grueneberg DA, Yang X, et al: A
lentiviral RNAi library for human and mouse genes applied to an
arrayed viral high-content screen. Cell. 124:1283–1298. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gartel AL and Kandel ES: RNA interference
in cancer. Biomol Eng. 23:17–34. 2006. View Article : Google Scholar
|
|
34
|
Cockrell A and Kafri T: Gene delivery by
lentivirus vectors. Mol Biotechnol. 36:184–204. 2007. View Article : Google Scholar
|
|
35
|
Porter AG and Jänicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
